Johnson & Johnson
These 10 medications are likely targets for Medicare price negotiations this fall
Merck & Co. Inc. Januvia brand medication, used to treat type2 diabetes, sit on a pharmacy shelf in Princeton, Illinois. Daniel Acker | Bloomberg | Getty Images Medicare is poised to directly negotiate drug prices with the pharmaceutical industry this fall for the first time in the program’s nearly six-decade history. The Centers for Medicare […]
Read More
Novavax shares jump after Covid vaccine maker posts surprise quarterly profit
Medical syringes and Novavax logo displayed in the background are seen in this illustration photo taken in Krakow, Poland on December 2, 2021. Jakub Porzycki | NurPhoto | Getty Images Shares of Novavax jumped as much as 20% in premarket trading Tuesday after the Covid vaccine maker reported a surprise second-quarter profit. The results come […]
Read More
Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%
Sopa Images | Lightrocket | Getty Images Eli Lilly on Tuesday raised its full-year guidance as second-quarter profit jumped 85% from the same period a year ago on strong sales from the pharmaceutical giant’s drug pipeline. The company now expects full-year revenue of between $33.4 billion to $33.9 billion, up from a previous forecast of […]
Read More
Here are the 5 price-target changes and 4 trades we made during this busy earnings week
In a jam-packed week of earnings, the Club executed multiple trades and elevated price targets for some of our biggest stocks. Many of these moves stemmed from what we saw in quarterly numbers and heard on conference calls. Here’s a day-by-day look at the portfolio action. Monday The week began with our decision to exit […]
Read More
We’re exiting a health-care name — putting us on the hunt to buy a new stock for the portfolio
We’re taking a hard look at the Bullpen and the rest of the market for new opportunities. Source
Read More
Johnson & Johnson effort to resolve talc cancer lawsuits in bankruptcy fails a second time
In this photo illustration, a container of Johnson and Johnson baby powder is displayed on April 05, 2023 in San Anselmo, California. Justin Sullivan | Getty Images A federal bankruptcy judge on Friday rejected Johnson & Johnson‘s second attempt to resolve tens of thousands of lawsuits alleging the company’s talc baby powder and other talc-based […]
Read More
Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer
Kenvue, a unit of Johnson & Johnson’s consumer health business. CFOTO | Future Publishing | Getty Images Johnson & Johnson on Monday said it plans to reduce by at least 80% its stake in Kenvue, the consumer health business it spun out as an independent company earlier this year, via a stock exchange offer. J&J […]
Read More
Kenvue CEO says consumers are spending on brand-name health products even as they pull back in other areas
Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson’s consumer-health business, speaks during an interview to celebrate its IPO at the New York Stock Exchange (NYSE), May 4, 2023. Brendan Mcdermid | Reuters Most consumers have pulled back on spending as inflation squeezes their wallets, but they have not stopped paying up for brand-name […]
Read More
Here’s what Jim Cramer thinks about J&J stock after a pivotal talc case verdict
A closely watched talc trial in California goes against Johnson & Johnson (JNJ), adding uncertainty around whether tens of thousands of other plaintiffs suing the company will sign on to J & J’s proposed $8.9 billion settlement offer or seek to get their own days in court. Jim Cramer believes the biopharmaceutical company was “too […]
Read More
Ford’s dividend quality, J&J’s split-off, cost basis discipline — what we think about all these
Send your questions directly to Jim Cramer and his team of analysts at [email protected] . Reminder, we can’t offer personal investing advice. We will only consider more general questions about the investment process or stocks in the portfolio or related industries. Question 1: What are your thoughts on the stability of FORD’s dividend? Thank you, Denise The quickest […]
Read More